Small intestinal bacterial overgrowth (SIBO) is a common, yet underrecognized, problem. Its
prevalence is unknown because SIBO requires diagnostic testing. Although abdominal …

Background Small intestinal bacterial overgrowth (SIBO) is a heterogeneous syndrome,
characterised by an increased number and/or abnormal type of bacteria in the small bowel …

Human intestinal microbiota create a complex polymicrobial ecology. This is characterised
by its high population density, wide diversity and complexity of interaction. Any dysbalance …

The pathogenesis of irritable bowel syndrome (IBS), once thought to be largely psychogenic
in origin, is now understood to be multifactorial. One of the reasons for this paradigm shift is …

Background Small intestinal bacterial overgrowth (SIBO) is an under‐recognised diagnosis
with important clinical implications when untreated. However, the optimal treatment regimen …

BACKGROUND & AIMS: Bacteria might be involved in the development and persistence of
inflammation in patients with Crohn's disease (CD), and antibiotics could be used in therapy …

Rifaximin is effective for the treatment of travelers' diarrhea and can be considered as the
treatment of choice for uncomplicated travelers' diarrhea. When invasive travelers' diarrhea …

Objectives Many studies have linked irritable bowel syndrome (IBS) with small intestinal
bacterial overgrowth (SIBO), although they have done so on a qualitative basis using breath …

Irritable bowel syndrome (IBS) is a chronic disorder characterized by abdominal pain,
change in bowel habit, and bloating. It has traditionally been viewed as a disorder of visceral …

Rifaximin, with its low systemic absorption, may represent a treatment of choice for irritable
bowel syndrome (IBS), mainly due to its ability to act on IBS pathogenesis, through the …